Vascular Biology

Rapid Restoration of Normal Endothelial Functions in Genetically Hyperlipidemic Mice by a Synthetic Mediator of Reverse Lipid Transport

Kevin Jon Williams, Rosario Scalia, Kirstin D. Mazany, Wendi V. Rodrigueza, Allan M. Lefer
https://doi.org/10.1161/01.ATV.20.4.1033
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1033-1039
Originally published April 1, 2000

Jump to

Abstract

Abstract—Endothelial dysfunction is a major pathophysiological consequence of hypercholesterolemia and other conditions. We examined whether a synthetic mediator of lipid transport from peripheral tissues to the liver (ie, the “reverse” pathway) could restore normal endothelial function in vivo. Using assays of macrovascular and microvascular function, we found that genetically hypercholesterolemic apolipoprotein E knockout mice exhibited key endothelial impairments. Treatment of the mice for 1 week with daily intravenous bolus injections of large “empty” phospholipid vesicles, which accelerate the reverse pathway in vivo, restored endothelium-dependent relaxation, leukocyte adherence, and endothelial expression of vascular cell adhesion molecule-1 to normal or nearly normal levels. These changes occurred despite the long-standing hyperlipidemia of the animals and the persistence of high serum concentrations of cholesterol-rich atherogenic lipoproteins during the treatment. Our results indicate that dysfunctional macrovascular and microvascular endothelium in apolipoprotein E knockout mice can recover relatively quickly in vivo and that accelerated reverse lipid transport may be a useful therapy.

  • Reprint requests to Dr Kevin Jon Williams, The Dorrance H. Hamilton Research Laboratories, Division of Endocrinology, Diabetes & Metabolic Diseases, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, 1020 Locust St, Room 349, Philadelphia, PA 19107-6799.

  • Presented as a preliminary report at the 71st Scientific Sessions of the American Heart Association, Dallas, Tex, November 8–11, 1998, and published in abstract form (Circulation. 1998;98[suppl I]:I-732–I-733).

  • Received May 11, 1999.
  • Accepted November 3, 1999.

In hypercholesterolemic animals and humans, the endothelium of medium-sized muscular arteries, such as the coronary arteries, loses its ability to release biologically available nitric oxide, a vasodilator required for endothelium-dependent relaxation of vessels in response to ADP, acetylcholine, hypoxia, and other stimuli.1 2 3 4 5 6 Furthermore, in hypercholesterolemia, the luminal surface of vascular endothelium displays abnormally high levels of P-selectin and vascular cell adhesion molecule-1 (VCAM-1). On the venous but not the arterial side,6 7 these endothelial cell adhesion molecules mediate leukocyte rolling (tethering) and adherence (immobilization), respectively, by binding to counterreceptors on the leukocytes.8 9 10 These changes in the macrovasculature and microvasculature occur early, within 1 to 2 weeks after the onset of atherogenic hypercholesterolemia,3 6 8 9 10 well before overt atherosclerosis has developed. In humans, lowering the plasma concentration of LDL and other cholesterol-rich atherogenic lipoproteins that deliver harmful lipids into the vessel wall11 12 has been reported to improve endothelium-dependent vasomotor regulation after several months,4 5 13 14 although full normalization of endothelium-dependent relaxation is uncommon4 5 13 and may require the simultaneous administration of antioxidants15 16 or extreme measures to lower LDL levels.17 18 Similarly, elevated plasma concentrations of soluble cell adhesion molecules seen in human hyperlipidemias respond only minimally to aggressive drug treatments to lower plasma lipid levels.19 The therapeutic approach of LDL lowering, with or without the coadministration of antioxidants, presumably attenuates further dysfunction of the endothelium and then relies on endogenous pathways for removal of harmful lipids to gradually improve endothelial function.

We sought a different approach, namely, the determination of whether direct interventions that accelerate lipid transport from the vascular wall to the liver could rapidly restore endothelial function in vivo, even in the continued presence of long-term hypercholesterolemia. Until recently, there was no easy potent method to accelerate reverse lipid transport in vivo without harmful side effects. Drugs that increase plasma concentrations of HDL, the apparent natural mediator of the reverse pathway, are relatively ineffective, and direct injection of HDL or HDL-like artificial particles, though antiatherogenic in animals under some circumstances,20 21 is technically arduous. Moreover, injections of small HDL-like particles can provoke the side effect of raising plasma LDL levels,22 23 24 25 which appears to be a hepatic response to the extra cholesterol load.24 Adenovirus-mediated gene delivery to rapidly enhance hepatic expression of the scavenger receptor BI, a receptor for HDL, leads to the enhanced uptake of HDL lipids by the liver and then to a very large prolonged rise in the plasma concentrations of atherogenic lipoproteins.26 In the present study, we accelerated reverse lipid transport in vivo through daily intravenous bolus injections of cholesterol-free, large, “empty” phospholipid vesicles (LEVs), where empty indicates the absence of encapsulated drugs. Phospholipid vesicles were shown to act as antiatherogenic cholesterol sinks in plasma before their ultimate removal by the liver24 27 28 29 30 31 32 (see also Reference 3333 ). Such particles have little or no effect on erythrocyte composition30 32 or on the serum parameters of liver function in rodents (D.P. Rosenbaum, unpublished data, 1999). Importantly, the liver can accommodate large amounts of cholesterol from LEVs without causing a rise in plasma concentrations of LDL or suppression of hepatic LDL receptor message.24 25 To study the dysfunctional endothelium, we used the apoE knockout mouse, which has been widely investigated because of its spontaneous development of lifelong hypercholesterolemia and accelerated atherosclerosis.34

Methods

Preparation of LEVs and Clearance Study

Synthetic 99% pure 1-palmitoyl,2-oleoyl phosphatidylcholine (Avanti Polar Lipids) was chosen because of its fluidity at body temperature yet strong resistance to oxidation. After hydration in saline, the lipid was made into LEVs (≈100 to 200 nm) by extrusion, as previously described.24 30 31 For the clearance studies, trace amounts of [3H]cholesteryl hexadecyl ether, a nonhydrolyzable lipid that remains associated with liposomes in the absence of cholesteryl ester transfer protein, were included to follow the particles.30 Wild-type and apoE knockout mice, 3.5 to 4.0 months of age, in the C57BL/6 background (Jackson Laboratory, Bar Harbor, Me) received a single bolus injection of labeled LEVs (300 mg/kg) via the tail vein. Blood samples were taken over a 5-day period; then the animals were killed, and organ radioactivity was determined. All animal studies were conducted in accordance with the Thomas Jefferson University Animal Care and Use Committee.

Endothelium-Dependent Relaxation in Aortic Rings

The basic approach for assessing endothelium-dependent relaxation of isolated aortic rings follows previous descriptions.3 Thoracic aortas were removed from mice anesthetized with pentobarbital sodium (120 mg/kg); the aortas were then placed into ice-cold Krebs-Henseleit buffer.3 Surrounding tissue was dissected away, and great care was taken to avoid injury to the endothelium. Aortic rings (≈2 mm) were mounted isometrically in aerated baths at 37°C under a resting force of 0.5 g and allowed to equilibrate for 90 minutes before the administration of any agents. Rings were contracted with 10 nmol/L U46619 (9,11-methanoepoxyprostaglandin H2), a thromboxane A2 mimetic, and then relaxed with the agents listed in Figure 1⇓. Isometric contractions were measured with Grass FT-03 force transducers (Grass Instruments). Fresh bath solution was added after each test response to reequilibrate the rings to baseline values. Because A23187, the calcium ionophore, is not completely reversible, it was always tested last.

Figure 1.
Figure 1.

Impairment of endothelium-dependent relaxation in aortic rings from genetically hypercholesterolemic apoE knockout (KO) mice and enhancement to normal levels after treatment with LEVs for 1 week. Values are mean±SEM (n=5 to 7). Statistical comparisons were performed by ANOVA, followed by pairwise comparisons by the 2-tailed t test with the Bonferroni correction. Data from wild-type control mice and LEV-treated apoE KO mice were statistically indistinguishable. *P<0.05, **P<0.02, and ***P<0.001 vs saline-treated apoE KO mice.

Intravital Microscopy

Intravital microscopy to assess leukocyte-endothelium interactions was performed in anesthetized mice by following standard procedures for other species9 but was adapted in the present study to mouse peri-intestinal venules, as previously described.35 Each mouse was initially anesthetized with sodium pentobarbital (120 mg/kg IP), and a loop of intestine was exposed through a midline laparotomy and kept moist on a heated microscope stage by superfusion of warm oxygenated Krebs-Henseleit buffer. A second abdominal incision in the right flank was made to administer additional anesthetic, as needed. Mice were allowed to stabilize for 20 minutes after surgery. A Microphot microscope (Nikon Corp) was used to visualize the mesenteric microcirculation, and a 30- to 50-μm-diameter postcapillary venule in peri-intestinal fat on the serosal surface of the intestine was chosen for observation. The image was projected by a high-resolution video color camera (DC-330, DAGE-MTI, Inc) onto a high-resolution color video monitor (Multiscan 200-sf, Sony Corp) and recorded on a videocassette recorder. Red blood cell velocity was determined online with an optical Doppler velocimeter (Microcirculation Research Institute), which allows for calculation of venular shear rates. The numbers of rolling and adhered leukocytes were quantified offline by playback of the videotape. Leukocytes were considered to be rolling if they were moving significantly more slowly than the red blood cells. Rolling was expressed as the number of such cells moving past a designated point per minute (ie, flux). A leukocyte was judged to be adherent if it remained stationary for >30 seconds. Adherence was expressed as the number of such cells per 100 μm of vessel length during 2-minute periods of observation at 0, 15, and 30 minutes after stabilization. The adherence values in each intravital preparation remained stable over this entire time period.

Repetitive LEV Injections

ApoE knockout mice received daily intravenous bolus injections of LEVs (1000 mg/kg) or the equivalent volume of saline, beginning Friday afternoon and ending the following Friday morning, for a total of 8 injections over the course of just under 1 week. Notice that this course of therapy is far shorter than one previously used to shrink arterial lesions.32 Three hours after the last dose, mice were euthanized for the harvesting of aortas or anesthetized for intravital microscopy. Blood samples for lipid and apoB assays were taken before any injections and just before euthanasia. In control experiments to examine nonspecific effects of LEVs on leukocyte-endothelium interactions, apoE knockout mice were injected with a single dose of LEVs (1250 mg/kg), and wild-type mice were given 8 daily injections of LEVs (1000 mg/kg) and then evaluated with intravital microscopy.

LEV-Cytokine Binding

To determine whether LEVs bind key cytokines, 125I-labeled interleukin-1β (0.2 ng/mL) or tumor necrosis factor-α (0.4 ng/mL, Amersham Corp) was incubated for 1 hour at 37°C with serum obtained from LEV-treated apoE knockout mice. The mixture was then subjected to size-exclusion chromatography by passage over a column of BioGel A-15m (1.5×27 cm, Bio-Rad Corp) that had been calibrated to distinguish LEVs, LDL, HDL, and albumin. In parallel experiments using a serum-free system, 125I-labeled cytokines were incubated with BSA (0.4%), without or with LEVs (24 mg/mL), and then passed over the BioGel column. Radioactivity associated with LEVs was assessed by gamma counting the column fractions and then correcting for counts that eluted in the LEV size range but in the absence of LEVs (presumably, aggregated labeled material).

Quantitative Immunohistochemistry

Quantitative immunohistochemistry of ileal venules was performed as previously described.9 Tissue sections of ileum were incubated with a primary antibody against either mouse P-selectin (PB 1.3, Cytel Corp) or mouse VCAM-1 (MVCAM.A-429, Endogen) at a dilution of 1:100 for 24 hours. Biotinylated secondary antibody was then added, followed by avidin-peroxidase, and staining was developed with 3,3′-diaminobenzidine. Positive staining was defined as brown reaction product on >50% of the circumference of a given venule. Fifty ileal venules per tissue section and 10 sections per mouse were examined in a blinded fashion, and the percentage of positive staining was tallied.

Results

Because apoE is involved in specific pathways for particle clearance36 37 and may play a role in cholesterol removal from cells,38 we began by examining the consequences of a single intravenous bolus injection of LEVs into apoE-deficient mice. The rise in the plasma concentration of unesterified cholesterol, which reflects the mobilization of tissue cholesterol by liposomes,27 28 29 30 tended to be slightly higher in the apoE knockout mice than in the wild-type mice (75±17 versus 50±7.0 mg/dL, respectively, at 8 hours after the injection; mean±SEM, n=4; P=NS), similar to previous findings in other hyperlipidemic animals.29 39 The overall rate of LEV clearance was similar between apoE knockout and wild-type mice (24 hours after the injection, 22.6±2.9% and 23.3±2.4% of the injected dose remained in serum in the 2 respective groups of mice; P=NS), with no difference in hepatic accumulation of LEV label. Thus, LEVs mobilize tissue cholesterol and then are cleared by the liver in both apoE knockout and wild-type mice, demonstrating that these particles mediate reverse lipid transport in vivo even in the absence of apoE.

Next, we used 2 methods of assessing endothelial function in mice: (1) endothelium-dependent relaxation of isolated aortic rings and (2) leukocyte rolling and adherence in postcapillary peri-intestinal venules by intravital microscopy. Vascular rings from wild-type female mice relaxed 61±5% (mean±SEM, n=18) to 10 μmol ADP/L, whereas rings from wild-type males relaxed only 9±3% (n=10), and a sex difference was evident down to 10 nmol ADP/L. The finding is presumably a consequence of higher oxidative stress in male aortas,40 although this remains a controversial area.41 42 ADP did not relax deendothelialized mouse aortic rings. All subsequent experiments with aortic rings were conducted with female mice. Leukocyte rolling and adherence showed no sex differences in either wild-type or apoE-deficient mice, which allowed the use of both sexes.

Aortic rings were analyzed from the following groups of female mice: normolipidemic wild-type mice (plasma total cholesterol 56±3 mg/dL) and apoE knockout mice (baseline plasma total cholesterol 528±76 mg/dL) that were treated with daily intravenous bolus injections of either saline or LEVs for 8 consecutive days. Similar to prior results in other systems,2 3 4 6 43 44 we found substantially impaired relaxation to ADP, a receptor-dependent endothelium-dependent vasodilator, and to the calcium ionophore A23187, a receptor-independent endothelium-dependent agent, in apoE-deficient mice compared with wild-type control mice (Figure 1⇑, top and middle panels). Relaxation to NaNO2, an endothelium-independent vasodilator, was unaltered in the apoE knockout mice (Figure 1⇑, bottom panel).

At the end of the treatment period, the apoE knockout mice that had been given LEV injections exhibited far higher plasma unesterified cholesterol concentrations (643±29 mg/dL, n=5) than did the saline-injected apoE knockout mice (150±12 mg/dL, n=5), reflecting mobilization of tissue stores of cholesterol by the circulating vesicles, as previously described.24 27 28 29 30 32 Plasma phospholipid concentrations were also substantially increased (LEV-treated mice, 24.3±2.5 mg/mL; saline-treated mice, 3.29±0.30 mg/mL). The short course of LEV treatments did not affect plasma levels of esterified cholesterol (LEV-treated mice, 283±15 mg/dL; saline-treated mice, 272±42 mg/dL; P=NS) or murine apoB (LEV-treated mice, 676±58 mg/L; saline-treated mice, 660±71 mg/L; P=NS),45 indicating unaltered plasma concentrations of atherogenic lipoproteins (see Reference 24 ). Nevertheless, LEV treatments of apoE-deficient mice enhanced the responsiveness of their aortic rings to the 2 endothelium-dependent agents up to levels statistically indistinguishable from the responsiveness seen in rings from normolipidemic wild-type control mice (Figure 1⇑).

We next examined microvascular endothelial function. Consistent with prior evidence that hypercholesterolemia in other species upregulates cell adhesion molecules,6 8 9 10 we found large increases in leukocyte rolling and adherence in apoE-deficient mice compared with normolipidemic wild-type control mice, indicative of an inflammatory state (Figure 2⇓). Treatment of the apoE-deficient animals with LEVs for 1 week produced a small statistically insignificant rise in rolling but a markedly attenuated leukocyte adherence compared with values seen in normal wild-type mice (Figure 2⇓). In contrast, 1 week of LEV injections into wild-type mice produced no effect on baseline leukocyte-endothelium interactions (Figure 2⇓, legend), indicating the absence of any global inhibitory effect from repeated administration. As a test for nonspecific interactions of LEVs with upregulated cell adhesion molecules or their counterreceptors, the presence of LEVs for 30 minutes in vivo in otherwise-untreated apoE null mice produced the same small statistically insignificant rise in rolling seen after 1 week of LEV injections but had no effect on leukocyte adherence compared with values in saline-treated apoE null mice (Figure 2⇓, rightmost bars). None of these interventions had any effect on blood leukocyte counts, which averaged from 5.9±0.6 to 7.2±0.4 (103 cells/mm3) in each of the 5 experimental groups in Figure 2⇓ (P=0.3 by ANOVA). Similarly, hemodynamic parameters were indistinguishable among the 5 groups (average venular shear rates ranged from 605±33 to 620±45 s−1, P>0.9; mean arterial blood pressures ranged from 118±3 to 128±6 mm Hg, P=0.24). Consistent with the functional results in Figure 2⇓, microvascular endothelium in apoE-deficient mice showed increased surface expression of P-selectin and VCAM-1 proteins. LEV injections for 1 week did not affect P-selectin but substantially suppressed VCAM-1 (Figures 3⇓ and 4⇓), consistent with our quantification of rolling and adherence in these mice.

Figure 2.
Figure 2.

Increased leukocyte rolling and adherence to endothelium of postcapillary peri-intestinal venules in hypercholesterolemic apoE KO mice and effects of treatment with LEVs for 1 week. A, Quantification of leukocyte rolling on endothelium of wild-type mice (open bars, n=7), apoE KO mice treated with saline for 1 week (solid bars, n=4), apoE KO mice treated with LEVs for 1 week (hatched bars, n=4), and apoE KO mice 30 minutes after a single LEV injection (shaded bars, n=6). B, Quantification of leukocyte-endothelial adherence in the same 4 groups of mice. *P<0.01 vs wild-type control mice; †P<0.01 vs apoE KO mice treated with LEVs for 1 week. Values in wild-type mice given daily injections of LEVs for 1 week were 7.38±0.94 rolling cells/min and 1.88±0.66 adhering cells/100 μm (n=4), which are statistically indistinguishable from the data in the leftmost bars of panels A and B (P>0.5).

Figure 3.
Figure 3.

Increased P-selectin and VCAM-1 protein expression in endothelium of postcapillary ileal venules in hypercholesterolemic apoE KO mice and effects of treatment with LEVs for 1 week. A randomly selected subset of the mice used in Figure 2⇑ was studied. A, Quantification of surface expression of P-selectin on the endothelium of ileal venules from wild-type mice (open bars, n=3) and apoE KO mice treated with saline for 1 week (solid bars, n=3) or with LEVs for 1 week (hatched bars, n=3). B, Quantification of surface expression of VCAM-1 on the endothelium of ileal venules from the same 3 groups of mice. *P<0.01 vs wild-type control mice; †P<0.01 vs LEV-treated apoE KO mice.

Figure 4.
Figure 4.

Representative images of VCAM-1 immunostaining in ileal venules from wild-type mice (top) and apoE KO mice treated with saline for 1 week (middle) or with LEVs for 1 week (bottom). V indicates venule lumen, and the arrows indicate marked endothelial staining.

Finally, to determine whether LEVs might act by adsorbing, and hence removing, key cytokines, we examined the binding of 125I-labeled interleukin-1β and tumor necrosis factor-α to LEVs in vitro. Virtually all labeled material remained as free protein. On the basis of the sensitivity of our assay, <0.2 pg of cytokine was bound per milligram of LEV phospholipid, suggesting that cytokine adsorption by LEVs is not an important contributor to the biological effects of these particles.

Discussion

Direct enhancement of reverse lipid transport in vivo represents a novel approach to ameliorate the major sequelae of elevated plasma concentrations of atherogenic lipoproteins.24 25 27 28 29 32 These sequelae include endothelial dysfunction, platelet hyperreactivity, and atherosclerosis, including the development of lipid-rich rupture-prone plaques. Our data indicate that treatment with LEVs, which accelerate reverse lipid transport in vivo without reducing long-standing elevations in plasma concentrations of cholesterol-rich atherogenic lipoproteins, is sufficient to rapidly restore important indices of macrovascular and microvascular endothelial function to normal. Although it is possible that there are actions of LEVs independent of accelerated reverse lipid transport that may have contributed to the effects we observed, our data eliminated 2 conspicuous mechanistic possibilities, namely, nonspecific interference of LEVs with leukocyte-endothelium interactions and adsorption by LEVs of key cytokines.

Although the pathophysiological effects of atherogenic hyperlipidemia on the endothelium are complex and incompletely understood, several potential factors that contribute to this problem have been identified, and there is evidence indicating how these factors can be favorably affected by phospholipid liposomes. The first contributory factor is oxidized substances, chiefly from oxidized LDL. In hypercholesterolemic patients, the best improvements in endothelium-dependent vascular reactivity have been reported after administration of lipid-lowering agents in combination with antioxidants,13 16 and the degree of improvement correlates with the resistance of the patient’s LDL to oxidation.15 Oxidized LDL impairs endothelium-dependent relaxation of isolated coronary arterial and aortic segments,46 and lipid components of oxidized LDL, such as lysophosphatidylcholine47 48 and oxysterols,49 50 reduce the endothelial release of nitric oxide,48 50 inhibit the relaxation of isolated aortic rings,49 and induce surface displays of endothelial cell adhesion molecules in vitro and in vivo.47 48 Incubation of modified LDL with phospholipid complexes impairs its uptake by cells,51 and toxic oxidized lipids are readily redistributed from oxidized LDL onto LEVs (W.V.R., Tammy R. Dugas, K.J.W., unpublished data, 1998). Furthermore, liposomes made of 1-palmitoyl,2-oleoyl phosphatidylcholine, as we used in the present study, donate large amounts of this oxidation-resistant phospholipid onto native LDL during coincubations in vitro (see References 28 and 5228 52 ) and presumably remove phospholipids with readily oxidizable polyunsaturated side chains, thereby rendering the LDL resistant to oxidation and oxidation-induced aggregation (W.V.R., Tammy R. Dugas, K.J.W., unpublished data, 1998). Any oxidized or oxidizable lipids acquired by the liposomes in vivo would be transported from lipoproteins and the arterial wall into the liver, which is the site of liposome catabolism.27 29

The second contributory factor in hypercholesterolemia-induced vascular dysfunction is native unoxidized LDL. Recent studies indicate that native LDL induces acute and chronic elevations in cytosolic calcium concentrations,53 activator protein-1–dependent gene transcription,54 and VCAM-1 expression53 in cultured endothelial cells. Increases in cytosolic calcium concentrations by LDL may result in part from structural alterations in intracellular55 and plasma56 membranes caused by the donation of unesterified cholesterol from LDL to cells. The ability of phospholipid liposomes to extract unesterified cholesterol from cellular membranes has been shown in vitro to reverse changes in membrane structure and calcium flux.56

The third contributory factor is low plasma concentrations of HDL. In coronary patients, low levels of HDL are associated with severe impairments of endothelium-dependent vascular reactivity.57 58 HDL has been shown to inhibit the oxidation of LDL in vitro,59 60 and HDL can block harmful effects of oxidized LDL on endothelial cells,61 62 because HDL can take up abnormal lipids, such as lysophosphatidylcholine61 and oxidized sterols.62 HDL and artificial HDL-like complexes can temporarily alter cultured endothelial cells to be resistant to subsequent activation by cytokines,63 64 and the mechanism appears to involve scavenging of cellular pro-oxidant molecules by these particles.64 In addition, HDL removes unoxidized cholesterol from cells, particularly after the cells have accumulated cholesterol from atherogenic lipoproteins.65 LEVs substantially enhance the ability of HDL to extract cellular lipids, both through remodeling the HDL into a better lipid acceptor and by acting as a large-capacity sink for lipids shuttled out of cells by HDL.27 28 31

Our results are consistent with the model that high plasma concentrations of atherogenic lipoproteins induce endothelial dysfunction through several contributory pathways.5 For example, P-selectin expression and leukocyte rolling in the microvasculature were differently regulated from the other parameters we measured, consistent with prior work.6 10 In contrast, endothelium-dependent relaxation, leukocyte adherence, and VCAM-1 expression all returned to normal or nearly normal levels with LEV treatment. Earlier investigation has shown parallel regulation of these parameters,6 66 which has been attributed to a role for nitric oxide in both endothelium-dependent relaxation and the suppression of surface expression of endothelial cell adhesion molecules.9 Moreover, parallel regulation of these specific endothelial functions between the macrovasculature and microvasculature indicates that one can be a marker for the others.6

Endothelial dysfunction is a major factor in poor regulation of blood flow, increased platelet aggregation, and recruitment of inflammatory cells into the vessel wall. Overall, our results indicate that direct interventions to enhance reverse lipid transport in vivo, presumably in conjunction with conventional therapies, may be a useful approach to restore normal macrovascular and microvascular endothelial cell physiology in atherogenic hyperlipidemia.

Acknowledgments

This study was supported by research grants from Baxter Healthcare Corp and from Talaria Therapeutics, Inc to Dr Williams and by National Institutes of Health grant GM-45434 to Dr Lefer. During this study, Dr Williams was an Established Investigator of the American Heart Association and Genentech. Dr Rodrigueza was supported by a Research Fellowship from the Heart & Stroke Foundation of British Columbia and Yukon (Canada) and then by a postdoctoral fellowship from the American Heart Association, Southeastern Pennsylvania Affiliate. The authors thank Dr Daniel M. Levine for his biochemical assays of serum.

References

  1. ↵
    Scalia R, Rodrigueza WV, Mazany KD, Lefer AM, Williams KJ. Large unilamellar phospholipid vesicles (LUV) accelerate reverse lipid transport and normalize endothelial function in hyperlipidemia apo-E knock-out mice. Circulation. 1998;98(suppl I):I-732–I-733. Abstract.
  2. ↵
    Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046–1051.
    OpenUrlCrossRefPubMed
  3. ↵
    Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits: reversal with lovastatin treatment. J Clin Invest. 1989;83:465–473.
  4. ↵
    Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481–487.
    OpenUrlCrossRefPubMed
  5. ↵
    Lüscher TF, Tanner FC, Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr Opin Lipidol. 1996;7:234–240.
    OpenUrlPubMed
  6. ↵
    Scalia R, Appel JZ III, Lefer AM. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: role of P-selectin, ICAM-1, and VCAM-1. Arterioscler Thromb Vasc Biol. 1998;18:1093–1100.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Ley K, Gaehtgens P. Endothelial, not hemodynamic, differences are responsible for preferential leukocyte rolling in rat mesenteric venules. Circ Res. 1991;69:1034–1041.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb. 1993;13:771–776.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:1652–1659.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Sakai A, Kume N, Nishi E, Tanoue K, Miyasaka M, Kita T. P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Arterioscler Thromb Vasc Biol. 1997;17:310–316.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551–561.
    OpenUrlFREE Full Text
  12. ↵
    Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol. 1998;9:471–474.
    OpenUrlCrossRefPubMed
  13. ↵
    Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488–493.
    OpenUrlCrossRefPubMed
  14. ↵
    Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467–471.
    OpenUrlCrossRefPubMed
  15. ↵
    Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 1996;93:1647–1650.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Neunteufl T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, Weidinger F. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol.. 1998;32:711–716.
    OpenUrlCrossRefPubMed
  17. ↵
    Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;95:76–82.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R, Notohamiprodjo G. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis. 1998;139:173–178.
    OpenUrlCrossRefPubMed
  19. ↵
    Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996;93:1334–1338.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234–1241.
  21. ↵
    Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998;97:780–785.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Stone BG, Schrieber D, Alleman LD, Ho C-Y. Hepatic metabolism and secretion of a cholesterol-enriched lipoprotein fraction. J Lipid Res. 1987;28:162–172.
    OpenUrlAbstract
  23. ↵
    Kuivenhoven JA, Demacker PNM, Stalenhoef AFH, Pajkrt D, van Deventer SJH, Doran JE, Pritchard PH, Kastelein JJP. Infusion of reconstituted HDL: reverse cholesterol transport in hereditary HDL deficiencies. Circulation. 1996;94(suppl I):I-343–I-344. Abstract.
  24. ↵
    Rodrigueza WV, Mazany KD, Essenburg AD, Pape ME, Rea TJ, Bisgaier CL, Williams KJ. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools: implications for the treatment of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2132–2139.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Williams KJ, Rodrigueza WV. Atherosclerosis: cell biology and lipoproteins: bad ways to raise the ‘good’ cholesterol. Curr Opin Lipidol. 1998;9:511–513.
    OpenUrlCrossRefPubMed
  26. ↵
    Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414–417.
    OpenUrlCrossRefPubMed
  27. ↵
    Williams KJ, Werth VP, Wolff JA. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect Biol Med. 1984;27:417–431.
    OpenUrlPubMed
  28. ↵
    Williams KJ, Scanu AM. Uptake of endogenous cholesterol by a synthetic lipoprotein. Biochim Biophys Acta. 1986;875:183–194.
    OpenUrlPubMed
  29. ↵
    Williams KJ, Vallabhajosula S, Rahman IU, Donnelly TM, Parker TS, Weinrauch M, Goldsmith SJ. Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis. Proc Natl Acad Sci U S A. 1988;85:242–246.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Rodrigueza WV, Pritchard PH, Hope MJ. The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo. Biochim Biophys Acta. 1993;1153:9–19.
    OpenUrlPubMed
  31. ↵
    Rodrigueza WV, Williams KJ, Rothblat GH, Phillips MC. Remodeling and shuttling: mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler Thromb Vasc Biol. 1997;17:383–393.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim Biophys Acta. 1998;1368:306–320.
    OpenUrlPubMed
  33. ↵
    Friedman M, Byers SO, Rosenman RH. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc Soc Exp Biol Med. 1957;95:586–588.
    OpenUrl
  34. ↵
    Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468–471.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Scalia R, Armstead VE, Minchenko AG, Lefer AM. Essential role of P-selectin in the initiation of the inflammatory response induced by hemorrhage and reinfusion. J Exp Med. 1999;189:931–938.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Mahley RW, Ji ZS, Brecht WJ, Miranda RD, He D. Role of heparan sulfate proteoglycans and the LDL receptor-related protein in remnant lipoprotein metabolism. Ann N Y Acad Sci. 1994;737:39–52.
    OpenUrlCrossRefPubMed
  37. ↵
    Fuki IV, Kuhn KM, Lomazov IR, Rothman VL, Tuszynski GP, Iozzo RV, Swenson TL, Fisher EA, Williams KJ. The syndecan family of proteoglycans: novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest. 1997;100:1611–1622.
    OpenUrlCrossRefPubMed
  38. ↵
    Zhang WY, Gaynor PM, Kruth HS. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem. 1996;271:28641–28646.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Friedman M, Byers SO. Enhancement of phosphatide-induced hypercholesterolemia by prior ingestion of cholesterol and triglyceride. Am J Physiol. 1958;192:546–548.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Brandes RP, Mügge A. Gender differences in the generation of superoxide anions in the rat aorta. Life Sci. 1997;60:391–396.
    OpenUrlCrossRefPubMed
  41. ↵
    Kauser K, Rubanyi GM. Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae. Am J Physiol. 1994;267:H2311–H2317.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, Korach KS. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta: gender difference and effect of estrogen receptor gene disruption. J Clin Invest. 1997;99:2429–2437.
    OpenUrlCrossRefPubMed
  43. ↵
    Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 1997;17:2333–2340.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Barton M, Haudenschild CC, d’Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1998;95:14367–14372.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Levine DM, Williams KJ. Automated measurement of mouse apolipoprotein B: convenient screening tool for mouse models of atherosclerosis. Clin Chem. 1997;43:669–674.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Tanner FC, Noll G, Boulanger CM, Luscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 1991;83:2012–2020.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138–1144.
  48. ↵
    Scalia R, Murohara T, Campbell B, Kaji A, Lefer AM. Lysophosphatidylcholine stimulates leukocyte rolling and adherence in rat mesenteric microvasculature. Am J Physiol. 1997;272:H2584–H2590.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Deckert V, Persegol L, Viens L, Lizard G, Athias A, Lallemant C, Gambert P, Lagrost L. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins: cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation. 1997;95:723–731.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Deckert V, Brunet A, Lantoine F, Lizard G, Millanvoyevanbrussel E, Monier S, Lagrost L, Daviddufilho M, Gambert P, Devynck MA. Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1054–1060.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Miyazaki A, Sakai M, Suginohara Y, Hakamata H, Sakamoto Y, Morikawa W, Horiuchi S. Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J Biol Chem. 1994;269:5264–5269.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Shahrokh Z, Nichols AV. Particle size interconversion of human low density lipoproteins during incubation of plasma with phosphatidylcholine vesicles. Biochem Biophys Res Commun. 1982;108:888–895.
    OpenUrlPubMed
  53. ↵
    Allen S, Khan S, Al-Mohanna F, Batten P, Yacoub M. Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest. 1998;101:1064–1075.
    OpenUrlCrossRefPubMed
  54. ↵
    Zhu Y, Lin JHC, Liao HL, Friedli O, Verna L, Marten NW, Straus DS, Stemerman MB. LDL induces transcription factor activator protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:473–480.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Kutryk MJ, Pierce GN. Stimulation of sodium-calcium exchange by cholesterol incorporation into isolated cardiac sarcolemmal vesicles. J Biol Chem. 1988;263:13167–13172.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Bialecki RA, Tulenko TN, Colucci WS. Cholesterol enrichment increases basal and agonist-stimulated calcium influx in rat vascular smooth muscle cells. J Clin Invest. 1991;88:1894–1900.
  57. ↵
    Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol. 1991;68:1425–1430.
    OpenUrlCrossRefPubMed
  58. ↵
    Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 1994;89:2525–2532.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    van Hinsbergh VW, Scheffer M, Havekes L, Kempen HJ. Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim Biophys Acta. 1986;878:49–64.
    OpenUrlPubMed
  60. ↵
    Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243–253.
    OpenUrlCrossRefPubMed
  61. ↵
    Schmidt K, Klatt P, Graier WF, Kostner GM, Kukovetz WR. High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase. Biochem Biophys Res Commun. 1992;182:302–308.
    OpenUrlCrossRefPubMed
  62. ↵
    Sugiyama S, Kugiyama K, Matsumura T, Suga S, Itoh H, Nakao K, Yasue H. Lipoproteins regulate C-type natriuretic peptide secretion from cultured vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1995;15:1968–1974.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987–1994.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 1997;238:61–65.
    OpenUrlCrossRefPubMed
  65. ↵
    Pieters MN, Schouten D, van Berkel TJ. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta. 1994;1225:125–134.
    OpenUrlPubMed
  66. ↵
    Krejcy K, Schwarzacher S, Ferber W, Plesch C, Cybulsky MI, Weidinger FF. Expression of VCAM-1 in rabbit iliac arteries is associated with vasodilator dysfunction of regenerated endothelium following balloon injury. Atherosclerosis. 1996;122:59–67.
    OpenUrlCrossRefPubMed
View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Rapid Restoration of Normal Endothelial Functions in Genetically Hyperlipidemic Mice by a Synthetic Mediator of Reverse Lipid Transport
    Kevin Jon Williams, Rosario Scalia, Kirstin D. Mazany, Wendi V. Rodrigueza and Allan M. Lefer
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1033-1039, originally published April 1, 2000
    https://doi.org/10.1161/01.ATV.20.4.1033
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects